Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3068 in advanced solid tumors
NCT03518554Phase 1Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JAB-3068 in solid tumor, non-small cell lung cancer (NSCLC), head and neck cancer (HNC) and 1 more, sponsored by Jacobio Pharmaceuticals. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Apr 2018; status: completed.
02
Drugs
JAB-3068
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck cancer (HNC)esophageal cancer
Beyond the preview
Go deeper on NCT03518554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518554.